Allogenic benefit in stem cell therapy: Cardiac repair and regeneration

Tissue Antigens

Volumn 86, Issue 3, 2015, Pages 155-162

  Al Daccak, Reem ^a   Charron, Dominique ^a  

^a INSERM   (France)

Author keywords

Allogenicity; Cardiac repair; Cardiac derived stem progenitor cells; Stem cell based therapy

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; CARDIAC REGENERATION; CARDIAC REPAIR; HEART SURGERY; HUMAN; IMMUNOGENICITY; MACROPHAGE; MEDICAL RESEARCH; MONOCYTE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATION; REVIEW; ALLOTRANSPLANTATION; HEART; HEART FAILURE; IMMUNOMODULATION; PHYSIOLOGY; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH;

HEART; HEART FAILURE; HUMANS; IMMUNOMODULATION; REGENERATION; STEM CELL TRANSPLANTATION; TRANSLATIONAL MEDICAL RESEARCH; TRANSPLANTATION, HOMOLOGOUS;

EID: 84938998718     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12614     Document Type: Review

References (57)

1. Drukker M, Katchman H, Katz G et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 2006: 24: 221-9.
2. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011: 474: 212-5.
3. Charron D, Suberbielle-Boissel C, Al-Daccak R. Immunogenicity and allogenicity: a challenge of stem cell therapy. J Cardiovasc Transl Res 2009: 2: 130-8.
4. Dhodapkar KM, Feldman D, Matthews P et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci USA 2010: 107: 8718-23.
5. Charron D, Suberbielle-Boissel C, Tamouza R, Al-Daccak R. Anti-HLA antibodies in regenerative medicine stem cell therapy. Hum Immunol 2012: 73: 1287-94.
6. Drukker M, Katz G, Urbach A et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA 2002: 99: 9864-9.
7. Tarte K, Gaillard J, Lataillade JJ et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010: 115: 1549-53.
8. Bocelli-Tyndall C, Zajac P, Di Maggio N et al. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 2010: 62: 3815-25.
9. Erlich HA, Opelz G, Hansen J. HLA DNA typing and transplantation. Immunity 2001: 14: 347-56.
10. Kofidis T, deBruin JL, Tanaka M et al. They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. Eur J Cardiothorac Surg 2005: 28: 461-6.
11. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 2005: 80: 555-63.
12. Crespo M, Yelamos J, Redondo D et al. Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies. Am J Transplant 2015: 15: 806-14.
13. Moreau A, Varey E, Anegon I, Cuturi MC. Effector mechanisms of rejection. Cold Spring Harb Perspect Med 2013: 3. DOI: 10.1101/cshperspect.a015461.
14. Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005: 17: 541-5.
15. Lefaucheur C, Loupy A, Vernerey D et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013: 381: 313-9.
16. Li F, Atz ME, Reed EF. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr Opin Immunol 2009: 21: 557-62.
17. Clatworthy MR, Espeli M, Torpey N, Smith KG. The generation and maintenance of serum alloantibody. Curr Opin Immunol 2010: 22: 669-81.
18. Tan Y, Ooi S, Wang L. Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives. Curr Stem Cell Res Ther 2014: 9: 63-72.
19. Mohsin S, Siddiqi S, Collins B, Sussman MA. Empowering adult stem cells for myocardial regeneration. Circ Res 2011: 109: 1415-28.
20. Hare JM, Traverse JH, Henry TD et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009: 54: 2277-86.
21. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003: 114: 763-76.
22. Blin G, Nury D, Stefanovic S et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 2010: 120: 1125-39.
23. Makkar RR, Smith RR, Cheng K et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012: 379: 895-904.
24. Menasche P. Stem cells in the management of advanced heart failure. Curr Opin Cardiol 2015: 30: 179-85.
25. Bolli R, Chugh AR, D'Amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011: 378: 1847-57.
26. Malliaras K, Marban E. Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br Med Bull 2011: 98: 161-85.
27. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011: 109: 923-40.
28. Tseliou E, Pollan S, Malliaras K et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J Am Coll Cardiol 2013: 61: 1108-19.
29. Kim J, Shapiro L, Flynn A. The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease. Pharmacol Ther 2015: 151: 8-15.
30. Lauden L, Boukouaci W, Borlado LR et al. Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. Circ Res 2013: 112: 451-64.
31. Boukouaci W, Lauden L, Siewiera J et al. Natural killer cell crosstalk with allogeneic human cardiac-derived stem/progenitor cells controls persistence. Cardiovasc Res 2014: 104: 290-302.
32. Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 2012: 18: 128-34.
33. Lohan P, Coleman CM, Murphy JM, Griffin MD, Ritter T, Ryan AE. Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned? Stem Cell Res Ther 2014: 5: 99. DOI: 10.1186/scrt488.
34. Akyurekli C, Le Y, Richardson RB, Fergusson D, Tay J, Allan DS. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Rev 2015: 11: 150-60.
35. Boyle AJ, McNiece IK, Hare JM. Mesenchymal stem cell therapy for cardiac repair. Methods Mol Biol 2010: 660: 65-84.
36. Chimenti I, Smith RR, Li TS et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 2010: 106: 971-80.
37. Li TS, Cheng K, Malliaras K et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol 2012: 59: 942-53.
38. Malliaras K, Li TS, Luthringer D et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 2012: 125: 100-12.
39. Malliaras K, Smith RR, Kanazawa H et al. Validation of contrast-enhanced magnetic resonance imaging to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction. Circulation 2013: 128: 2764-75.
40. Oberbarnscheidt MH, Zeng Q, Li Q et al. Non-self recognition by monocytes initiates allograft rejection. J Clin Invest 2014: 124: 3579-89.
41. Abdi R, Means TK, Ito T et al. Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol 2004: 172: 767-75.
42. Zecher D, van Rooijen N, Rothstein DM, Shlomchik WD, Lakkis FG. An innate response to allogeneic nonself mediated by monocytes. J Immunol 2009: 183: 7810-6.
43. Oberbarnscheidt MH, Lakkis FG. Innate allorecognition. Immunol Rev 2014: 258: 145-9.
44. Arana M, Gavira JJ, Pena E et al. Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. Biomaterials 2014: 35: 143-51.
45. Hachem RR, Reinsmoen NL. What is the definition of a clinically relevant donor HLA-specific antibody (DSA)? Am J Transplant 2015: 15: 299-300.
46. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow Transplant 2007: 13: 412-22.
47. Schu S, Nosov M, O'Flynn L et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012: 16: 2094-103.
48. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007: 83: 783-90.
49. Cho PS, Messina DJ, Hirsh EL et al. Immunogenicity of umbilical cord tissue derived cells. Blood 2008: 111: 430-8.
50. Deuse T, Seifert M, Phillips N et al. Immunobiology of naive and genetically modified HLA-class-I-knockdown human embryonic stem cells. J Cell Sci 2011: 124: 3029-37.
51. Valenzuela NM, Reed EF. The link between major histocompatibility complex antibodies and cell proliferation. Transplant Rev 2011: 25: 154-66.
52. Al-Daccak R, Mooney N, Charron D. MHC class II signaling in antigen-presenting cells. Curr Opin Immunol 2004: 16: 108-13.
53. Gourraud PA, Gilson L, Girard M, Peschanski M. The role of human leukocyte antigen matching in the development of multiethnic "haplobank" of induced pluripotent stem cell lines. Stem Cells 2012: 30: 180-6.
54. Duquesnoy RJ, Howe J, Takemoto S. HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation 2003: 75: 889-97.
55. Duquesnoy RJ, Takemoto S, de Lange P et al. HLA matchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A, B amino acid triplet level on kidney transplant survival. Transplantation 2003: 75: 884-9.
56. Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004: 78: 190-3.
57. Pluchino S, Cossetti C. How stem cells speak with host immune cells in inflammatory brain diseases. Glia 2013: 61: 1379-401.